Requirement of helix 1 and the AF-2 domain of the thyroid hormone receptor for coactivation by PGC-1

被引:67
作者
Wu, YF [1 ]
Delerive, P [1 ]
Chin, WW [1 ]
Burris, TP [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
D O I
10.1074/jbc.M110761200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although PGC-1 (peroxisome proliferator-activated receptor-gamma coactivator-1) has been previously shown to enhance thyroid hormone receptor (TR)/retinoid X receptor-mediated ucp-1 gene expression in a ligand-induced manner in rat fibroblast cells, the precise mechanism of PGC-1 modulation of TR function has yet to be determined. In this study, we show that PGC-1 can potentiate TR-mediated transactivation of reporter genes driven by natural thyroid hormone response elements both in a ligand-dependent and ligand-independent manner and that the extent of coactivation is a function of the thyroid hormone response element examined. Our data also show that PGC-1 stimulation of TR activity in terms of Gal4 DNA-binding domain fusion is strictly ligand-dependent. In addition, an E457A AF-2 mutation had no effect on the ligand-induced PGC-1 enhancement of TR activity, indicating that the conserved charged residue in AF-2 is not essential for this PGC-1 function. Furthermore, GST pull-down and mammalian two-hybrid assays demonstrated that the PGC-1 LXXLL motif is required for ligand-induced PGC-1/TR interaction. This agonist-dependent PGC-1/TR interaction also requires both helix 1 and the AF-2 region of the TR ligand-binding domain. Taken together, these results support the notion that PGC-1 is a bona fide TR coactivator and that PGC-1 modulates TR activity via a mechanism different from that utilized with peroxisome proliferator activator receptor-gamma.
引用
收藏
页码:8898 / 8905
页数:8
相关论文
共 56 条
[1]   AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[2]   THE TAU-4 ACTIVATION DOMAIN OF THE THYROID-HORMONE RECEPTOR IS REQUIRED FOR RELEASE OF A PUTATIVE COREPRESSOR(S) NECESSARY FOR TRANSCRIPTIONAL SILENCING [J].
BANIAHMAD, A ;
LENG, XH ;
BURRIS, TP ;
TSAI, SY ;
TSAI, MJ ;
OMALLEY, BW .
MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (01) :76-86
[3]   CHARACTERIZATION OF THE LIGAND-DEPENDENT TRANSACTIVATION DOMAIN OF THYROID-HORMONE RECEPTOR [J].
BARETTINO, D ;
RUIZ, MDMV ;
STUNNENBERG, HG .
EMBO JOURNAL, 1994, 13 (13) :3039-3049
[4]   The histone acetylase PCAF is a nuclear receptor coactivator [J].
Blanco, JCG ;
Minucci, S ;
Lu, JM ;
Yang, XJ ;
Walker, KK ;
Chen, HW ;
Evans, RM ;
Nakatani, Y ;
Ozato, K .
GENES & DEVELOPMENT, 1998, 12 (11) :1638-1651
[5]   Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications [J].
Bourguet, W ;
Germain, P ;
Gronemeyer, H .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (10) :381-388
[6]   CAPACITY FOR COOPERATIVE BINDING OF THYROID-HORMONE (T3) RECEPTOR DIMERS DEFINES WILD TYPE-T3 RESPONSE ELEMENTS [J].
BRENT, GA ;
WILLIAMS, GR ;
HARNEY, JW ;
FORMAN, BM ;
SAMUELS, HH ;
MOORE, DD ;
LARSEN, PR .
MOLECULAR ENDOCRINOLOGY, 1992, 6 (04) :502-514
[7]  
BURRIS TP, 2000, NUCL RECEPTORS GENET, P1
[8]   Role of CBP/P300 in nuclear receptor signalling [J].
Chakravarti, D ;
LaMorte, VJ ;
Nelson, MC ;
Nakajima, T ;
Schulman, IG ;
Juguilon, H ;
Montminy, M ;
Evans, RM .
NATURE, 1996, 383 (6595) :99-103
[9]  
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[10]   Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300 [J].
Chen, HW ;
Lin, RJ ;
Schiltz, RL ;
Chakravarti, D ;
Nash, A ;
Nagy, L ;
Privalsky, ML ;
Nakatani, Y ;
Evans, RM .
CELL, 1997, 90 (03) :569-580